SEC Form 10-K filed by Scholar Rock Holding Corporation
$SRRK
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/26/2024 | $40.00 → $50.00 | Buy | H.C. Wainwright |
| 10/7/2024 | $30.00 → $35.00 | Buy | H.C. Wainwright |
| 3/28/2024 | $30.00 | Strong Buy | Raymond James |
| 10/25/2023 | $20.00 | Hold → Buy | Jefferies |
| 4/3/2023 | $26.00 | Overweight | Piper Sandler |
| 9/19/2022 | $30.00 | Buy | H.C. Wainwright |
| 7/12/2022 | $20.00 | Buy | Truist |
| 3/23/2022 | $24.00 | Buy | H.C. Wainwright |
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)
SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)
SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)
H.C. Wainwright reiterated coverage of Scholar Rock with a rating of Buy and set a new price target of $50.00 from $40.00 previously
H.C. Wainwright reiterated coverage of Scholar Rock with a rating of Buy and set a new price target of $35.00 from $30.00 previously
Raymond James initiated coverage of Scholar Rock with a rating of Strong Buy and set a new price target of $30.00
- Submitted apitegromab U.S. Biologics License Application (BLA) for patients with spinal muscular atrophy in January 2025; U.S. launch anticipated in 4Q 2025 - Remain on track to submit European Union marketing authorisation application (MAA) in 1Q 2025 - Topline data from Phase 2 EMBRAZE trial evaluating apitegromab vs placebo in adult patients with obesity receiving tirzepatide expected in 2Q 2025 - Filing of IND application for SRK-439, a highly selective investigational myostatin inhibitor designed for cardiometabolic indications, anticipated in 3Q 2025 - Ended 2024 with approximately $437 million in cash, cash equivalents, and marketable securities - Management to host updat
Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences: TD Cowen 45th Annual Health Care Conference: Scholar Rock is scheduled to participate in a fireside chat at 2:30 p.m. ET on Tuesday, March 4 in Boston. Wedbush Cardiometabolic Conference: Scholar Rock is scheduled to participate in a panel presentation at 10:05 a.m. ET on Monday, March 10 in Miami. Jefferies Biotech on the Bay Summit: Sch
Oral presentation to include additional efficacy data from the Phase 3 SAPPHIRE trial of apitegromab in patients with spinal muscular atrophy (SMA) Poster presentations include preclinical data on a combination treatment approach for building muscle mass and strength in a Duchenne muscular dystrophy (DMD) model Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, announced today that it will present additional data from its Phase 3 SAPPHIRE clinical trial (NCT05156320) at the 2025 Muscular
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences: TD Cowen 45th Annual Health Care Conference: Scholar Rock is scheduled to participate in a fireside chat at 2:30 p.m. ET on Tuesday, March 4 in Boston. Wedbush Cardiometabolic Conference: Scholar Rock is scheduled to participate in a panel presentation at 10:05 a.m. ET on Monday, March 10 in Miami. Jefferies Biotech on the Bay Summit: Sch
Oral presentation to include additional efficacy data from the Phase 3 SAPPHIRE trial of apitegromab in patients with spinal muscular atrophy (SMA) Poster presentations include preclinical data on a combination treatment approach for building muscle mass and strength in a Duchenne muscular dystrophy (DMD) model Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, announced today that it will present additional data from its Phase 3 SAPPHIRE clinical trial (NCT05156320) at the 2025 Muscular
Scholar Rock (NASDAQ:SRRK, the "Company")), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 371,500 shares of its common stock to eleven newly hired employees, consisting of inducement stock options to purchase an aggregate of 212,284 shares of common stock and inducement restricted stock units, covering an aggregate of 159,216 shares of its common stock. The awards are subject to all terms and conditions and other provisions set f
- Former Vice President and Global HR Head of Oncology and Pharma Development at Novartis brings extensive leadership experience focused on talent, culture, and diversity Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Caryn Parlavecchio as Chief Human Resources Officer. She will join the executive team, bringing more than 20 years of experience as a senior leader and strategic executive in the biotechnology and pharmaceutical industries. This press release features multimedia. View the full release here: https://www.businesswire.co
S-8 - Scholar Rock Holding Corp (0001727196) (Filer)
10-K - Scholar Rock Holding Corp (0001727196) (Filer)
8-K - Scholar Rock Holding Corp (0001727196) (Filer)